Vertex Pharmaceuticals (VRTX) Operating Margin (2009 - 2026)

Vertex Pharmaceuticals' Operating Margin history runs 18 years deep, the most recent figure standing at 38.1% for Q1 2026.

• In Q1 2026, Operating Margin rose 1536.0% year-over-year to 38.1%; the TTM figure through Mar 2026 stood at 38.31% (up 4500.0% YoY), while the FY2025 annual figure was 34.77%, up 3689.0% from the prior year.
• Operating Margin for Q1 2026 stood at 38.1%, up from 37.8% in the prior quarter.
• The five-year high for Operating Margin was 50.37% in Q2 2022, with the low at 132.85% in Q2 2024.
• The 5-year median for Operating Margin is 39.26% (2023), against an average of 29.95%.
• The sharpest annual moves came in 2024 and 2025: Operating Margin sank 17402 bps in 2024, then soared 17168 bps in 2025.
• Vertex Pharmaceuticals' Operating Margin stood at 44.88% in 2022, then decreased by 13 bps to 39.26% in 2023, then decreased by 10 bps to 35.23% in 2024, then rose by 7 bps to 37.8% in 2025, then grew by 1 bps to 38.1% in 2026.
• Business Quant data shows VRTX's Operating Margin at 38.1% in Q1 2026, 37.8% in Q4 2025, and 38.56% in Q3 2025.